弥散加权磁共振成像引导剂量绘画在诱导化疗联合同期放化疗治疗局部晚期鼻咽癌患者中的随机对照临床试验
这项前瞻性随机对照试验纳入260例III-IVa期鼻咽癌患者,1:1随机接受DWI引导剂量绘画调强放疗(A组130例)或常规MRI引导调强放疗(B组130例)。A组同步放化疗后完全缓解率为99.2%,B组为93.8%(P=.042);中位随访25个月,A组2年无病生存率为93.6%,B组为87.5%(P=.015),急性及晚期毒性反应无统计学显著差异。
要点
- DWI引导剂量绘画调强放疗组完全缓解率为99.2%(129/130),常规MRI调强放疗组为93.8%(122/130),P=.042。
- 中位随访25个月,DWI引导组2年无病生存率为93.6%,常规MRI组为87.5%(P=.015)。
- 两组急性及晚期毒性反应无统计学显著差异,最常见首发失败部位均为远处器官转移。
核心结论
- 在局部晚期鼻咽癌患者中,与常规MRI引导调强放疗相比,DWI引导剂量绘画调强放疗联合同期化疗与无病生存获益相关,且未增加急性毒性反应。
研究设计与样本
- 前瞻性随机对照临床试验,纳入260例III-IVa期鼻咽癌患者,按1:1随机分为DWI引导剂量绘画调强放疗组(A组,n=130)和常规MRI引导调强放疗组(B组,n=130)。
- A组在诱导化疗前MRI上定义GTVnx-DWI为GTVnx内表观扩散系数低于平均ADC的区域,T1-2期患者剂量提升至75.2 Gy/32次,T3-4期患者提升至77.55 Gy/33次,每次2.35 Gy。
- B组计划大体肿瘤体积鼻咽照射70.4至72.6 Gy/32至33次,每次2.2 Gy。
- 试验注册号为ChiCTR1800015779。
主要发现
- 放化疗后完全缓解率A组为99.2%(129/130),B组为93.8%(122/130),P=.042。
- 中位随访25个月,2年无病生存率A组为93.6%(95%CI 88.1%-99.1%),B组为87.5%(95%CI 81.4%-93.6%),P=.015。
- 2年局部无复发生存率A组为100%(95%CI不适用),B组为91.3%(95%CI 85.4%-97.2%);局部区域无复发生存率A组为95.8%(95%CI不适用),B组为91.3%(95%CI 85.4%-97.2%)。
- 2年无远处转移生存率A组为97.8%(95%CI不适用),B组为90.9%(95%CI 85.8%-96.0%);总生存率A组为100%(95%CI不适用),B组为94.5%(95%CI 89.2%-99.8%)。
- A组0例、B组3例发生单纯局部复发;两组急性及晚期毒性反应无统计学显著差异;多因素分析显示剂量绘画与无病生存、局部无复发生存、局部区域无复发生存及无远处转移生存相关,EB病毒DNA水平与无病生存及局部区域无复发生存相关。
关键数值与推荐
- A组GTVnx-DWI定义为诱导化疗前MRI上GTVnx内ADC低于平均ADC的区域。
- A组T1-2期患者GTVnx-DWI剂量为75.2 Gy/32次,T3-4期患者为77.55 Gy/33次,每次2.35 Gy。
- B组计划大体肿瘤体积鼻咽剂量为70.4至72.6 Gy/32至33次,每次2.2 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We hypothesized that diffusion-weighted magnetic resonance imaging (DWI)-guided dose-painting intensity modulated radiation therapy (DP-IMRT) is associated with improved local tumor control and survival in locoregionally advanced nasopharyngeal carcinoma (NPC). The purpose of this randomized study was to compare the efficacy and toxicity of DWI-guided DP-IMRT to conventional magnetic resonance imaging (MRI)-based IMRT in locoregional advanced NPC. METHODS AND MATERIALS: A total of 260 patients with stage III-IVa NPC disease were randomly assigned in a 1:1 ratio to receive induction chemotherapy followed by chemoradiotherapy by DWI-guided DP-IMRT (group A, n = 130) or conventional MRI-based IMRT (group B, n = 130) in this prospective clinical trial. In group A, subvolume GTVnx-DWI (gross tumor volume of nasopharynx in DWI) was defined as the areas within the GTVnx (gross tumor volume of nasopharynx) with an apparent diffusion coefficient (ADC) below the mean ADC (ADC < mean) according to MRI before induction chemotherapy. The dose to GTVnx-DWI was escalated to 75.2 Gy/32 fx in patients with T1-2 disease and to 77.55 Gy/33 fx in those with T3-4 disease in 2.35 Gy per fraction. In group B, planning gross tumor volume of nasopharynx was irradiated at 70.4 to 72.6 Gy/32 to 33 fx in 2.2 Gy per fraction. This trial is registered with chictr.org.cn (ChiCTR1800015779). RESULTS: A total of 260 patients were included in the trial (130 patients in group A and 130 in group B). Complete response rates after chemoradiotherapy were 99.2% (129 of 130) and 93.8% (122 of 130) in groups A and B, respectively (P = .042). At a median follow-up of 25 months, DWI-guided DP-IMRT was associated with improved 2-year disease-free survival (DFS; 93.6% [95% confidence interval {CI}, 88.1%-99.1%] vs 87.5% [95% CI, 81.4%-93.6%], P = .015), local recurrence-free survival (100% [95% CI, not applicable {NA}] vs 91.3% [95% CI, 85.4%-97.2%]), locoregional recurrence-free survival (LRRFS; 95.8% [95% CI, NA] vs 91.3% [95% CI, 85.4%-97.2%]), distant metastasis-free survival (DMFS; 97.8% [95% CI, NA] vs 90.9% [95% CI, 85.8%-96.0%]), and overall survival (100% [95% CI, NA] vs 94.5% [95% CI, 89.2%-99.8%]). Zero and 3 patients had local-only recurrences in group A and B, respectively. The most common site of first failure in each arm was distant organ failure. No statistically significant differences in acute and late toxic effects were observed. Multivariate analyses showed that DP (DWI-guided DP-IMRT vs conventional MRI-based IMRT without DP) was associated with DFS, local recurrence-free survival, LRRFS, and distant metastasis-free survival. Epstein-Barr virus DNA level was associated with DFS and LRRFS. CONCLUSIONS: DWI-guided DP-IMRT plus chemotherapy is associated with a disease-free survival benefit compared with conventional MRI-based IMRT among patients with locoregionally advanced NPC without increasing acute toxic effects.
引用
- Fu S, Li Y, Han Y, et al. Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 35074433. doi:10.1016/j.ijrobp.2021.12.175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。